DK1267925T3 - Behandling af svampeinfektion mod antifungale polyener eller beta-glucansyntesehæmmere kombineret med anti-hsp90-antistoffer - Google Patents
Behandling af svampeinfektion mod antifungale polyener eller beta-glucansyntesehæmmere kombineret med anti-hsp90-antistofferInfo
- Publication number
- DK1267925T3 DK1267925T3 DK01911971T DK01911971T DK1267925T3 DK 1267925 T3 DK1267925 T3 DK 1267925T3 DK 01911971 T DK01911971 T DK 01911971T DK 01911971 T DK01911971 T DK 01911971T DK 1267925 T3 DK1267925 T3 DK 1267925T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- beta
- fungal infection
- synthesis inhibitors
- glucan synthesis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Botany (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0008305.5A GB0008305D0 (en) | 2000-04-06 | 2000-04-06 | Treatment of fungal infections |
| PCT/GB2001/001195 WO2001076627A1 (en) | 2000-04-06 | 2001-03-20 | Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1267925T3 true DK1267925T3 (da) | 2007-10-15 |
Family
ID=9889204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01911971T DK1267925T3 (da) | 2000-04-06 | 2001-03-20 | Behandling af svampeinfektion mod antifungale polyener eller beta-glucansyntesehæmmere kombineret med anti-hsp90-antistoffer |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20030180285A1 (pt) |
| EP (4) | EP1852128A1 (pt) |
| JP (1) | JP2003530357A (pt) |
| CN (3) | CN1420786A (pt) |
| AT (1) | ATE364396T1 (pt) |
| AU (2) | AU2001240890B2 (pt) |
| BR (1) | BR0109846A (pt) |
| CA (1) | CA2401836A1 (pt) |
| CY (1) | CY1106794T1 (pt) |
| DE (1) | DE60128893T2 (pt) |
| DK (1) | DK1267925T3 (pt) |
| ES (1) | ES2287105T3 (pt) |
| GB (1) | GB0008305D0 (pt) |
| NO (1) | NO20024815L (pt) |
| NZ (1) | NZ520899A (pt) |
| PL (1) | PL358394A1 (pt) |
| PT (1) | PT1267925E (pt) |
| RU (1) | RU2262952C2 (pt) |
| WO (1) | WO2001076627A1 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050129665A1 (en) * | 2002-07-25 | 2005-06-16 | Martin Friedlander | Isolated lineage negative hematopoietic stem cells and methods of treatment therewith |
| US7651689B2 (en) * | 2002-11-15 | 2010-01-26 | Albert Einstein College Of Medicine Of Yeshiva University | Methods of applying ionization radiation for therapy of infections |
| US7959915B2 (en) | 2003-03-12 | 2011-06-14 | Tufts University | Inhibitors of extracellular Hsp90 |
| EP1457499A1 (en) * | 2003-03-12 | 2004-09-15 | Tufts University School Of Medicine | Inhibitors of extracellular Hsp90 |
| GB0309126D0 (en) | 2003-04-17 | 2003-05-28 | Neutec Pharma Plc | Clostridium difficile focussed antibodies |
| GB0409077D0 (en) * | 2004-04-23 | 2004-05-26 | Neutec Pharma Plc | Treatment of fungal infections |
| CA2572318A1 (en) | 2004-07-02 | 2006-01-12 | Neutec Pharma Plc | Treatment of cancer |
| SG153877A1 (en) * | 2004-07-02 | 2009-07-29 | Neutec Pharma Plc | Treatment of cancer |
| WO2006091459A2 (en) * | 2005-02-24 | 2006-08-31 | Joslin Diabetes Center, Inc. | Compositions and methods for treating vascular permeability |
| JP5154406B2 (ja) * | 2005-04-13 | 2013-02-27 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| GB0600168D0 (en) * | 2006-01-05 | 2006-02-15 | Neutec Pharma Plc | A therapeutic composition |
| GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| WO2008091692A2 (en) * | 2007-01-25 | 2008-07-31 | Joslin Diabetes Center, Inc. | Methods of diagnosing, treating, and preventing increased vascular permeability |
| WO2008116216A1 (en) * | 2007-03-22 | 2008-09-25 | Medical College Of Georgia Research Institute, Inc. | Compositions and methods for inhibiting cancer metastasis |
| US20100113355A1 (en) * | 2007-04-27 | 2010-05-06 | Naresh Chennamsetty | Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90 |
| WO2008132174A1 (en) * | 2007-04-27 | 2008-11-06 | Novartis Ag | An immunoglobulin composition |
| US10457726B2 (en) | 2016-06-30 | 2019-10-29 | University Of Connecticut | Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof |
| CN113845591B (zh) * | 2018-10-30 | 2023-10-31 | 迈威(上海)生物科技股份有限公司 | Hsp90抗体及其在抗真菌感染中的应用 |
| CN111679069A (zh) * | 2019-12-31 | 2020-09-18 | 安徽中医药大学 | 一种通过耳道念珠菌细胞壁重构来评价中药单体抗真菌作用的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8915019D0 (en) * | 1989-06-30 | 1989-08-23 | Matthews Ruth C | Medicaments |
| GB2270076A (en) * | 1992-08-18 | 1994-03-02 | Univ Manchester | Human HSP 90 Epitopes |
| US6375955B1 (en) * | 1995-09-22 | 2002-04-23 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis |
| US6365165B1 (en) * | 1995-09-22 | 2002-04-02 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis |
| US5834592A (en) * | 1995-09-22 | 1998-11-10 | Corixa Corporation | Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis |
| US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
-
2000
- 2000-04-06 GB GBGB0008305.5A patent/GB0008305D0/en not_active Ceased
-
2001
- 2001-03-20 US US10/240,819 patent/US20030180285A1/en not_active Abandoned
- 2001-03-20 JP JP2001574143A patent/JP2003530357A/ja active Pending
- 2001-03-20 CN CN01807383A patent/CN1420786A/zh active Pending
- 2001-03-20 WO PCT/GB2001/001195 patent/WO2001076627A1/en active IP Right Grant
- 2001-03-20 AU AU2001240890A patent/AU2001240890B2/en not_active Ceased
- 2001-03-20 DE DE60128893T patent/DE60128893T2/de not_active Expired - Lifetime
- 2001-03-20 CA CA002401836A patent/CA2401836A1/en not_active Abandoned
- 2001-03-20 PT PT01911971T patent/PT1267925E/pt unknown
- 2001-03-20 RU RU2002129510/15A patent/RU2262952C2/ru not_active IP Right Cessation
- 2001-03-20 AT AT01911971T patent/ATE364396T1/de active
- 2001-03-20 EP EP07075462A patent/EP1852128A1/en not_active Withdrawn
- 2001-03-20 DK DK01911971T patent/DK1267925T3/da active
- 2001-03-20 CN CN200910167220A patent/CN101683525A/zh active Pending
- 2001-03-20 AU AU4089001A patent/AU4089001A/xx active Pending
- 2001-03-20 BR BR0109846-2A patent/BR0109846A/pt not_active IP Right Cessation
- 2001-03-20 PL PL01358394A patent/PL358394A1/xx not_active Application Discontinuation
- 2001-03-20 EP EP07075857A patent/EP2011512A1/en not_active Withdrawn
- 2001-03-20 ES ES01911971T patent/ES2287105T3/es not_active Expired - Lifetime
- 2001-03-20 NZ NZ520899A patent/NZ520899A/en not_active IP Right Cessation
- 2001-03-20 CN CNA2007101126651A patent/CN101095952A/zh active Pending
- 2001-03-20 EP EP01911971A patent/EP1267925B8/en not_active Expired - Lifetime
- 2001-03-20 EP EP07075188A patent/EP1818062A3/en not_active Withdrawn
-
2002
- 2002-10-04 NO NO20024815A patent/NO20024815L/no not_active Application Discontinuation
-
2007
- 2007-08-07 CY CY20071101053T patent/CY1106794T1/el unknown
- 2007-11-14 US US11/984,177 patent/US20100285029A1/en not_active Abandoned
-
2008
- 2008-03-20 US US12/076,643 patent/US20080193459A1/en not_active Abandoned
- 2008-03-21 US US12/076,705 patent/US20080181884A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1267925T3 (da) | Behandling af svampeinfektion mod antifungale polyener eller beta-glucansyntesehæmmere kombineret med anti-hsp90-antistoffer | |
| CY1116632T1 (el) | Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου | |
| CY2012019I1 (el) | Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20 | |
| DK2316852T3 (da) | Stabiliserede enkeltdomæne-antistoffer | |
| CY1112277T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
| CY1110783T1 (el) | Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων | |
| DK1578397T3 (da) | Humane monoklonale antistoffer mod CD25 | |
| CO6231038A2 (es) | Proteinas de union, incluyendo anticuerpos derivados de anticuerpo y fragmentos de anticuerpo que se unen especificamente a cd154 y sus usos | |
| NZ602256A (en) | Monoclonal antibodies against the rgm a protein and uses thereof | |
| ES2572231T3 (es) | Anticuerpos monoclonales anti-IL-21 humana | |
| CY1111622T1 (el) | Ανθρωποποιημενοι ανταγωνιστες anti-cmet | |
| NO20071436L (no) | Humaniserte Anti-5T4 antistoffer og Anti-5T4 antistoff/calicheamicin konjugater | |
| CL2008001258A1 (es) | Kit de vacuna que comprende al menos nueve conjugados de sacaridos de antgenos hb o hib, donde al menos 2-7 son con la proteina transportadora crm, siendo dicho kit adecuado para usar en su calendario de inmunizacion primaria; vacuna combinada adecuada para la inmunizacion primaria. | |
| CY1112288T1 (el) | Θεραπεια του καρκινου με αντισωματα κατα της il-1a | |
| DK2330132T3 (da) | Antistoffer mod MMP2 eller MMP9 og farmaceutiske sammensætninger deraf til hæmning af deres metalloproteinaktivitet | |
| AR055072A1 (es) | Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical | |
| CY1109121T1 (el) | Θεραπεια μυκητιασικων μολυνσεων | |
| ITRM20040105A1 (it) | Anticorpo monoclonale antitenascina umana. | |
| FI20011055A0 (fi) | Heveiiniä sitovat monoklonaaliset vasta-aineet | |
| DK1398325T3 (da) | Monoklonalt antistof, specifikt for en epitop af inaktiveret felint immundeficiens-kodet glykoprotein | |
| DK1503799T3 (da) | Immunogent, monoklonalt antistof | |
| BR0315018A (pt) | Uso de anticorpos dos receptores de il-2 para prevenir toxicidade associada à terapia antimicótica com anfotericina b | |
| CY1116949T1 (el) | M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου | |
| UA106870C2 (uk) | Антитіла, специфічні для протофібрилярної форми бета-амілоїдного білка |